This study describes patient-reported outcomes from the phase 3 IMmotion151 study to assess the safety and efficacy of atezolizumab in combination with bevacizumab in patients with untreated metastatic renal cell carcinoma (RCC) and who were positive for the PD-L1 biomarker. In this study, the patients treated with atezolizumab plus bevacizumab had longer progression-free survival compared with patients treated with sunitinib.
Patient reported outcomes (PROs) were evaluated in terms of overall treatment and disease burden using 3 patient questionnaires. In all, 454 patients were randomised to receive atezolizumab plus bevacizumab and 461 were randomised to receive sunitinib alone. Around 86% (389) of patients in the atezolizumab plus bevacizumab group and 83% (370) of patients in the sunitinib arm completed the questionnaires. Before receiving treatment, both groups of patients reported mild symptom severity and mild symptom interference with daily life.
Patient reported outcome data were collected throughout the study for about 114 weeks. Overall, patients taking atezolizumab plus bevacizumab reported milder symptoms, less symptom interference, and treatment side-effect bother, and better health-related quality of life than patients taking sunitinib.
In conclusion, patient-reported outcomes highlight the more favourable tolerability of atezolizumab plus bevacizumab compared with sunitinib. This study also highlights the importance of using patient-reported outcomes as endpoints in large clinical trials, which could be used to personalise and better support shared decision-making between the patient and the clinician in clinical practice.